DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,381 shares of the medical device company’s stock after selling 99 shares during the quarter. Rehmann Capital Advisory Group’s holdings in DexCom were worth $330,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. DSM Capital Partners LLC acquired a new position in DexCom in the fourth quarter valued at approximately $28,000. Riverview Trust Co purchased a new stake in shares of DexCom in the first quarter valued at approximately $32,000. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after buying an additional 103 shares in the last quarter. MV Capital Management Inc. increased its position in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares in the last quarter. Finally, Smithfield Trust Co increased its position in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on DXCM. Redburn Atlantic began coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Citigroup boosted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group boosted their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, Raymond James boosted their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.33.

DexCom Trading Down 0.2 %

Shares of DexCom stock traded down $0.17 during trading hours on Wednesday, hitting $110.67. The company’s stock had a trading volume of 1,283,211 shares, compared to its average volume of 2,888,789. The firm has a fifty day moving average of $120.40 and a 200-day moving average of $125.22. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a market cap of $44.01 billion, a price-to-earnings ratio of 71.61, a P/E/G ratio of 2.71 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. Research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 629 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now owns 68,212 shares in the company, valued at approximately $8,611,765. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,102 shares of company stock valued at $755,103. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.